Trial
NCT00570531
Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
Genentech, Inc.
Condition
Loco-regional Esophageal Cancer
Intervention
Bevacizumab
Why stopped
The study was unable the accrue the required number of patients within a reasonable time.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-26